Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

Graphical Abstract Graphical Abstract Practical considerations, potential barriers, and research gaps relating to sodium-glucose co-transporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in individuals with heart failure with preserved ejection fraction and obesity....

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 45; no. 30; pp. 2748 - 2751
Main Authors Ostrominski, John W, Solomon, Scott D, Vaduganathan, Muthiah
Format Journal Article
LanguageEnglish
Published UK Oxford University Press 09.08.2024
Subjects
Drug Therapy, Combination
Glucagon-Like Peptide-1 Receptor - agonists
Heart Failure - drug therapy
Humans
Hypoglycemic Agents - therapeutic use
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Stroke Volume - drug effects
Stroke Volume - physiology
Online AccessGet full text

Cover

More Information
Summary:Graphical Abstract Graphical Abstract Practical considerations, potential barriers, and research gaps relating to sodium-glucose co-transporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in individuals with heart failure with preserved ejection fraction and obesity. HF, heart failure; SGLT2i, sodium-glucose co-transporter 2 inhibitor
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0195-668X
1522-9645
1522-9645
DOI:10.1093/eurheartj/ehae414